P-195 YI Circulating Mirna Biomarkers in Inflammatory Bowel Disease
Emilie Viennois,Mark Baker,Bo Xiao,Saravanan Ayyadurai,Hamed Laroui,Didier Merlin
DOI: https://doi.org/10.1097/01.mib.0000438937.27640.a6
2013-01-01
Inflammatory Bowel Diseases
Abstract:Inflammatory bowel diseases (IBDs), principally ulcerative colitis (UC) and Crohn’s disease (CD), are chronic and progressive inflammatory disorders of the gastrointestinal tract. Current serum biomarkers for IBD such as lipocalin2 and Calprotectin are limited due to low specificity and predictive power. Serological assessments of IBD activity and early-stage diagnosis could thus be markedly improved through the use of a non-invasive serological biomarker signature such as miRNA. MiRNAs represent a class of naturally occurring small non-coding RNAs that have emerged as an important set of markers, as their plasma concentrations can emulate tissue- and disease-specific expression profiles. The interleukin-10 knockout (IL10−/−) mouse is a well-described model that reproducibly develops a time-dependent IBD that predominates in the colon and shares histopathological features with human UC. As the IL10−/− model mirrors the development and features of human IBD, it can be used to investigate miRNA expression profiles in circulating blood. We hypothesized that the time-course of the disease and its lesions can be correlated with specific miRNA profiles. Serum samples were collected from WT and IL10−/− mice once a week for 15 weeks. MiRNA profiles were analyzed using high-throughput technology, allowing us to study the kinetics of small changes in miRNA levels during the progression of intestinal inflammation. Among the 104 miRNAs tested, mmu-miR-29b, -122, -150, -192, -194, -146a and -375 were found to increase with disease progression, while mmu-miR-335-5p, -148a, -152, -140, -331-3p, -195, -140* and -199b decreased with disease progression. Statistical analyses revealed that among the miRNAs that were differentially expressed in colitic mice compared to non-colitic mice, 6 could be used as a profiling set that could very efficiently determine the inflammation status of the intestinal mucosa. Moreover, we found that the miRNA profiles were not identical between IL10−/− colitic mice and the DSS-induced colitis model, suggesting that miRNA signatures could be a powerful tool for discriminating between various types of intestinal inflammation (e.g., chronic versus acute and CD versus UC). These murine data may help establish miRNA patterns capable of predicting the diagnosis, prognosis, and therapeutic response in IBD. We used a mouse model to establish a putative miRNA signature of colitis, and established that it could be a useful tool for following the evolution of intestinal inflammation in mice. Future work is warranted to adapt this concept to human serum samples and eventually identify IBD-subtype-specific miRNA patterns in human patients.